Loss of PSMA Expression in Non-neuroendocrine Dedifferentiated Acinar Prostate Cancer

Clin Nucl Med. 2018 Jul;43(7):526-528. doi: 10.1097/RLU.0000000000002100.

Abstract

The introduction of tracers targeting the prostate-specific membrane antigen (PSMA) has revolutionized PET imaging of acinar prostate adenocarcinoma. In general, an increasing PSMA expression is assumed with increasing dedifferentiation. Whereas loss of PSMA expression has been reported in case of neuroendocrine dedifferentiation, we present a patient with acinar prostate adenocarcinoma with a loss of PSMA expression after chemotherapy on PET/CT and in histological and immunohistochemical analyses. All tissue samples indicated the retention of acinar features but no expression of neuroendocrine markers (NSE, synaptophysin, chromogranin, and CD56), corresponding to nonelevated serum NSE.

Publication types

  • Case Reports

MeSH terms

  • Adenocarcinoma / diagnostic imaging*
  • Adenocarcinoma / pathology
  • Aged
  • Edetic Acid / analogs & derivatives*
  • Edetic Acid / pharmacokinetics
  • Fluorodeoxyglucose F18
  • Gallium Isotopes
  • Gallium Radioisotopes
  • Humans
  • Male
  • Neoplasm Metastasis
  • Oligopeptides / pharmacokinetics*
  • Positron Emission Tomography Computed Tomography*
  • Prostatic Neoplasms / diagnostic imaging*
  • Prostatic Neoplasms / pathology
  • Radiopharmaceuticals / pharmacokinetics

Substances

  • Gallium Isotopes
  • Gallium Radioisotopes
  • Oligopeptides
  • Radiopharmaceuticals
  • gallium 68 PSMA-11
  • Fluorodeoxyglucose F18
  • Edetic Acid